Clinical Trials
57 trialsA Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
M.D. Anderson Cancer Center
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
C17 Council
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms
Affiliated Hospital to Academy of Military Medical Sciences
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
Beijing GoBroad Hospital
TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
Sun Yat-sen University
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
TCRCure Biopharma Ltd.
DA-EPOCH-R
Baylor College of Medicine
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
New York Medical College
A Study of N9 Chemotherapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
AIDS Malignancy Consortium
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
Thomas Jefferson University
Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies
Shanghai First Song Biotechnology Co., LTD
Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors
Peking University
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
Affiliated Hospital of Nantong University
SN301A
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
NEXTGENTIL-ACT
Vall d'Hebron Institute of Oncology
CARTinNS
Tongji Hospital
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
Shanghai First Song Biotechnology Co., LTD
GI-hNeoT-01
BGI, China
Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
University of Nebraska
Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
Albert Einstein College of Medicine
EBV CAR-T Cells for Nasopharyngeal Carcinoma
The Affiliated Hospital of Xuzhou Medical University
BGT007 Cell Treatment of Nasopharyngeal Carcinoma
The Affiliated Hospital of Xuzhou Medical University
TIL Cells for the Treatment of the Advanced Solid Tumors Patients
Fujian Cancer Hospital
TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
Fujian Cancer Hospital
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
The First People's Hospital of Lianyungang
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
Allife Medical Science and Technology Co., Ltd.
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
Xinqiao Hospital of Chongqing
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Xinqiao Hospital of Chongqing
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
Shanghai 6th People's Hospital
Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients
University Hospital, Ghent
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Intra-Osseous Co-Transplant of UCB and hMSC
Case Comprehensive Cancer Center
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
Hebei Senlang Biotechnology Inc., Ltd.
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia
Hebei Senlang Biotechnology Inc., Ltd.
Primary Breast Cancer Occurring Concomitant With Pregnancy
M.D. Anderson Cancer Center
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Zhejiang University
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Chemotherapy in Treating Patients With Sarcoma
Mayo Clinic